Thermodynamics of Trapped Imbalanced Fermi Gases at Unitarity

We present a theory for the low-temperature properties of a resonantly interacting Fermi mixture in a trap, that goes beyond the local-density approximation. The theory corresponds essentially to a Landau-Ginzburg-like approach that includes self-energy effects to account for the strong interactions at unitarity. We show diagrammatically how these self-energy effects arise from fluctuations in the superfluid order parameter. Gradient terms of the order parameter are included to account for inhomogeneities. This approach incorporates the state-of-the-art knowledge of the homogeneous mixture with a population imbalance exactly and gives good agreement with the experimental density profiles of Shin et al. [Nature 451, 689 (2008)]. This allows us to calculate the universal surface tension of the interface between the equal-density superfluid and the partially polarized normal state of the mixture. We also discuss the possibility of a metastable state to explain the deformation of the superfluid core that is seen in the experiment of Partridge et al. [Science 311, 503 (2006)].Comment: 26 pages, 7 figures, contribution to Lecture Notes in Physics "BCS-BEC crossover and the Unitary Fermi Gas" edited by W. Zwerge

Fermionic superfluidity: From high Tc superconductors to ultracold Fermi gases

We present a pairing fluctuation theory which self-consistently incorporates finite momentum pair excitations in the context of BCS--Bose-Einstein condensation (BEC) crossover, and we apply this theory to high $T_c$ superconductors and ultracold Fermi gases. There are strong similarities between Fermi gases in the unitary regime and high Tc superconductors. Here we address key issues of common interest, especially the pseudogap. In the Fermi gases we summarize recent experiments including various phase diagrams (with and without population imbalance), as well as evidence for a pseudogap in thermodynamic and other experiments.Comment: Expanded version, invited talk at the 5th International Conference on Complex Matter -- Stripes 2006, 6 pages, 6 figure

Double quantum dot turnstile as an electron spin entangler

We study the conditions for a double quantum dot system to work as a reliable electron spin entangler, and the efficiency of a beam splitter as a detector for the resulting entangled electron pairs. In particular, we focus on the relative strengths of the tunneling matrix elements, the applied bias and gate voltage, the necessity of time-dependent input/output barriers, and the consequence of considering wavepacket states for the electrons as they leave the double dot to enter the beam splitter. We show that a double quantum dot turnstile is, in principle, an efficient electron spin entangler or entanglement filter because of the exchange coupling between the dots and the tunable input/output potential barriers, provided certain conditions are satisfied in the experimental set-up.Comment: published version; minor error correcte

Total Cross Section in gamma gamma Collisions at LEP

The reaction e+e- -> e+e- gamma* gamma* -> e+e- hadrons for quasi-real photons is studied using data from root(s) = 183 GeV up to 202 GeV. Results on the total cross sections sigma(e+e- -> e+e- hadrons) and sigma(+e- gamma* gamma* -> e+e- hadrons) are given for the two-photon centre-of-mass energies 5 GeV < Wgammagamma < 185 GeV. The total cross section of two real photons is described by a Regge parametrisation. We observe a steeper rise with the two-photon centre-of-mass energy as compared to the hadron-hadron and the photon-proton cross sections. The data are also compared to the expectations of different theoretical models

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Survival Outcome Differences Based on Treatments Used and Knowledge of the Primary Tumour Site for Patients with Cancer of Unknown and Known Primary in Ontario

Introduction: Patients with cancer of unknown primary (CUP) have pathologically confirmed metastatic tumours with unidentifiable primary tumours. Currently, very little is known about the relationship between the treatment of patients with CUP and their survival outcomes. Thus, we compared oncologic treatment and survival outcomes for patients in Ontario with CUP against those for a cohort of patients with metastatic cancer of known primary site. Methods: Using the Ontario Cancer Registry and the Same-Day Surgery and Discharge Abstract databases maintained by the Canadian Institute for Health Information, we identified all Ontario patients diagnosed with metastatic cancer between 1 January 2000 and 31 December 2005. Ontario Health Insurance Plan treatment records were linked to identify codes for surgery, chemotherapy, or therapeutic radiation related to oncology. Multivariable Cox regression models were constructed, adjusting for histology, age, sex, and comorbidities. Results: In 45,347 patients (96.3%), the primary tumour site was identifiable, and in 1743 patients (3.7%), CUP was diagnosed. Among the main tumour sites, CUP ranked as the 6th largest. The mean Charlson score was significantly higher (p &lt; 0.0001) in patients with CUP (1.88) than in those with a known primary (1.42). Overall median survival was 1.9 months for patients with CUP compared with 11.9 months for all patients with a known-primary cancer. Receipt of treatment was more likely for patients with a known primary site (n = 35,012, 77.2%) than for those with CUP (n = 891, 51.1%). Among patients with a known primary site, median survival was significantly higher for treated than for untreated patients (19.0 months vs. 2.2 months, p &lt; 0.0001). Among patients with CUP, median survival was also higher for treated than for untreated patients (3.6 months vs. 1.1 months, p &lt; 0.0001). Conclusions: In Ontario, patients with CUP experience significantly lower survival than do patients with metastatic cancer of a known primary site. Treatment is associated with significantly increased survival both for patients with CUP and for those with metastatic cancer of a known primary site